• 2026.11.17 (Tue)
  • All articles
  • LOGIN
  • JOIN
Global Economic Times
한인동포뉴스(상단)
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Well+Being
    • Pet Life
    • Halal Horizon
  • Travel
  • Eco-News
  • Education
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life
    • International Student Report
    • With Ambassador
  • Column
    • Cho Kijo Column
    • Cherry Garden Story
    • Ko Yong-chul Column
    • Kim Bong-seon's Photo Column
    • Kim Seul-Ong Column
    • Lee Yeon-sil Column
    • Professor Lee Soo-young’s Life Essays
  • Photo News
  • New Book Guide
MENU
 
Home > Industry

US FDA Rejects Promising Chinese Bispecific Antibody, Altering the Landscape of Global Cancer Therapeutics

Ana Fernanda Reporter / Updated : 2026-11-17 06:55:29
  • -
  • +
  • Print


While giants like Pfizer and BMS accelerate next-generation oncology pipelines, South Korean biotechs eye potential tailwinds from impending U.S. supply chain restrictions.

The global oncology landscape has experienced a sudden shift after the U.S. Food and Drug Administration (FDA) declined marketing approval for ivonescimab, a high-profile Chinese bispecific antibody initially heralded as a potential challenger to Merck’s dominant blockbuster, Keytruda.

Developed by China’s Akeso Biopharma and licensed to U.S.-based Summit Therapeutics in a deal worth up to $5 billion, ivonescimab had previously stunned researchers. In Phase 3 trials involving Chinese non-small cell lung cancer (NSCLC) patients, the therapy cut the risk of disease progression or death by 49% compared to Keytruda, extending progression-free survival from 5.8 months to 11.1 months. These stellar numbers earned the drug a prestigious spotlight at the American Society of Clinical Oncology (ASCO) earlier this year, drawing comparisons to China’s technological triumphs in artificial intelligence.

However, the FDA issued a Complete Response Letter (CRL) denying the application. The regulatory body cited a lack of sufficient statistical proof regarding overall survival (OS) improvement. Furthermore, industry experts highlighted a geographic disparity in clinical trial demographics: over 60% of trial participants were of Asian descent, while Western patients accounted for only about 35%. Initial trials showed modest risk reduction in Western patient subsets, failing to meet the rigorous statistical thresholds required by U.S. regulators for overall survival benefits.

Despite this regulatory setback, Summit maintains that clinical trials for ivonescimab across other major indications—such as colorectal, breast, and bladder cancers—will continue globally.

Ripple Effects Across Global Pharma and the K-Bio Opportunity

The FDA's decision introduces fresh variables into the aggressive global race for next-generation cancer treatments:

Strategic Adjustments: AstraZeneca, which recently invested $2 billion into Summit to explore combination therapies utilizing ivonescimab alongside its proprietary antibody-drug conjugates (ADCs), now faces strategic delays regarding its U.S. commercialization timeline.
Intensifying Competition: Major pharmaceutical players, including Pfizer, BioNTech, and Bristol Myers Squibb, are continuing their own parallel developments of competing bispecific antibodies, while rival ADC developers eye an opening to capture market share in lung cancer treatments.
Potential Spillover for South Korean Biotechs: As Washington ramps up regulatory scrutiny on Chinese biotechnology—with the U.S. Biosecure Act framework moving forward—industry analysts believe South Korean drug developers such as Yuhan, ABL Bio, and Voronoi could capture strategic partnership opportunities as global pharma seeks alternative, secure supply chains.

[Copyright (c) Global Economic Times. All Rights Reserved.]

  • #Cherry Garden
  • #HalalFood
  • #Halal
  • #Petlife
  • #Halalhorizone
  • #Hormuz Impasse
  • #Joseon
  • #globaleconomictimes
  • #micore
Ana Fernanda Reporter
Ana Fernanda Reporter

Popular articles

  • US Army Conducts Rare Temporary Burial Drills to Prepare for Worst-Case Large-Scale War Scenarios

  • Saudi Aramco’s Astonishing Resilience: Crude Oil Transportation Resumes Days After Houthi Attacks

  • Ito En Enters Non-Alcoholic Market with Hop-Infused Tea Beverages

I like it
Share
  • Facebook
  • X
  • Kakaotalk
  • LINE
  • BAND
  • NAVER
  • https://www.globaleconomictimes.kr/article/1065563657414045 Copy URL copied.
Comments >

Comments 0

Weekly Hot Issue

  • Trump Questions Spy Allegations Surrounding Former Nvidia CEO and Alice Hwang
  • South Korea Eyes High 3% Growth on Semiconductor Boom, with 4% within Reach
  • Hanwha Pours 1.5 Trillion Won into U.S. Subsidiaries to Localize Production Beyond Exporting
  • From "Golden Grape" to 100 Million Dollar Turnaround: Shine Muscat’s Global Resurgence
  • Banks' Profitability Drops Despite Rate Hikes... Burdened by Higher Funding Costs
  • Global Energy Costs Surging: Crude and Jet Fuel Spikes Fuel Domestic Inflation Concerns

Most Viewed

1
South Korea and Ethiopia Sign Trilateral MOU to Introduce Liquid-Based Cytology (LBC) Technology for Cervical Cancer Diagnosis
2
Meeting Christmas Early!… Busan Dessert Sales Event "Daldal The Market" Held
3
World Citizens are Flying Directly to Busan... The Era of 4 Million Foreigners is Just Around the Corner
4
Eating 100g of Baechu Kimchi Daily Linked to Lower High-Cholesterol Risks
5
First Snow and Freeze Hit Korea as Winter Officially Begins on 'Ipdeong'
체리가든 스토리
nutri huevos
로타리
동포저널

Hot Issue

U.S. Transportation Secretary Urges Major Funding for Air Traffic Control System Following Massive Communications Failure

Tech Firms Spar Over AI Talent with Lucrative Sign-on Bonuses and Referral Perks

AI Semiconductor Stocks Plummet: Philadelphia Index Drops 5.28% and Micron Plunges 7.59% Amid Executive Shakeup and Export Restrictions

Fashion Runway Show 2026

Let’s recycle the old blankets in Jeju Island’s closet instead of incinerating them.

Global Economic Times
korocamia@naver.com
CEO : LEE YEON-SIL
Publisher : KO YONG-CHUL
Registration number : Seoul, A55681
Registration Date : 2024-10-24
Youth Protection Manager: KO YONG-CHUL
Singapore Headquarters
5A Woodlands Road #11-34 The Tennery. S'677728
Korean Branch
Phone : +82(0)10 4724 5264
#304, 6 Nonhyeon-ro 111-gil, Gangnam-gu, Seoul
Copyright © Global Economic Times All Rights Reserved
  • News K
  • 반달곰 프로젝트
  • 광고문의
Search
Category
  • All articles
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Well+Being 
    • 전체
    • Pet Life
    • Halal Horizon
  • Travel
  • Eco-News
  • Education
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life 
    • 전체
    • International Student Report
    • With Ambassador
  • Column 
    • 전체
    • Cho Kijo Column
    • Cherry Garden Story
    • Ko Yong-chul Column
    • Kim Bong-seon's Photo Column
    • Kim Seul-Ong Column
    • Lee Yeon-sil Column
    • Professor Lee Soo-young’s Life Essays
  • Photo News
  • New Book Guide
  • Overseas Koreans
  • Multicultural News